4//SEC Filing
CADENCE PHARMACEUTICALS INC 4
Accession 0001209191-13-052925
CIK 0001333248operating
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 6:39 PM ET
Size
8.8 KB
Accession
0001209191-13-052925
Insider Transaction Report
Form 4
Byrd Scott A.
SVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
stock option (right to buy)
2013-11-15−10,416→ 78,126 totalExercise: $3.51Exp: 2022-03-14→ common stock (10,416 underlying) - Exercise/Conversion
common stock
2013-11-15$3.51/sh+10,416$36,560→ 12,416 total - Sale
common stock
2013-11-15$8.00/sh−10,416$83,328→ 2,000 total
Footnotes (3)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2013.
- [F2]25% of the 125,000 shares of common stock originally subject to the option vested on 3/14/2013, and 1/48th of the remaining number of shares of common stock subject to the option vest on the first day of each full month thereafter.
- [F3]Not applicable to this transaction.
Documents
Issuer
CADENCE PHARMACEUTICALS INC
CIK 0001333248
Entity typeoperating
Related Parties
1- filerCIK 0001333248
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 6:39 PM ET
- Size
- 8.8 KB